A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT06318273. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer
Study identification
- NCT ID
- NCT06318273
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 230 participants
Conditions and interventions
Interventions
- ABBV-969 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 7, 2024
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
- Last update posted
- Apr 7, 2026
2024 – 2027
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope /ID# 262059 | Duarte | California | 91010 | Recruiting |
| Univ California, San Francisco /ID# 261715 | San Francisco | California | 94143-2204 | Recruiting |
| Yale University School of Medicine /ID# 262234 | New Haven | Connecticut | 06510 | Recruiting |
| AdventHealth Orlando /ID# 261686 | Orlando | Florida | 32803 | Recruiting |
| University of Chicago Medical Center /ID# 261605 | Chicago | Illinois | 60637 | Recruiting |
| START Midwest /ID# 264295 | Grand Rapids | Michigan | 49546 | Recruiting |
| Carolina BioOncology Institute /ID# 261602 | Huntersville | North Carolina | 28078 | Recruiting |
| Lifespan Cancer Institute at Rhode Island Hospital /ID# 261687 | Providence | Rhode Island | 02903-4923 | Recruiting |
| NEXT Oncology /ID# 261601 | San Antonio | Texas | 78229 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06318273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06318273 live on ClinicalTrials.gov.